In the 10-mg/kg arm, which is the dose used in the ongoing Phase III trials, median progression-free survival (PFS), or the time without disease progression, was 33 months after a median follow-up of 20.8 months and the objective response rate (ORR) was 92 percent...Median progression-free survival (PFS) was 13.9 months

Both progression-free survival (PFS) and overall survival (OS) improved with POM+LoDex compared to high-dose Dex (PFS: four months vs. 1.9 months, respectively; OS: 12.7 months vs. 8.1 months, respectively

Secondary endpoints include progression-free survival, safety, overall response and immune response...Key secondary endpoints include best response, duration of response and progression-free survival

The primary endpoints of the trial will be progression-free survival and overall survival

The primary endpoint of this trial is progression free survival

The primary endpoint for the trial is progression-free survival. (See BioWorld Today, Aug. 7, 2012

chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL) met its primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC

The median progression-free survival time was 5.6 months, and the median overall survival time could not be estimated as the survival rate did not fall below 50 percent

The randomized, open-label study will assess progression-free survival in about 140 patients given OGX-427 plus gemcitabine and carboplatin vs

However, patients with mutant RAS tumor status had inferior progression-free survival (HR = 1.34, 95 percent CI, 1.07-1.6) and OS (HR = 1.25, 95 percent CI, 1.02-1.55) when administered Vectibix in combination with Folfox compared to Folfox alone...Additionally, the length of time during which people lived without their disease worsening (median progression-free survival, PFS) was more than doubled (23 months compared to 10.9 months, HR = 0.14, 95 percent CI 0.09-0.21, p < 0.0001) when compared to

The primary endpoint in Phase II will be progression-free survival

Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II results published in the Journal of Clinical Oncology showed that HDAC inhibitor entinostat extended both progression-free survival (PFS) and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor

Eli Lilly and Co., of Indianapolis, said the Phase III PRELUDE study of enzastaurin, which explored the molecule as monotherapy in preventing relapse in patients with diffuse large B-cell lymphoma, failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy

Agenus Inc., of Lexington, Mass., said preliminary data from a Phase II trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (heat shock protein-peptide complex-96, HSPPC-96) vaccine plus the standard of care showed a 146 percent increase in progression-free survival (PFS) and a 60 percent increase in overall survival (OS) as compared to the standard of care alone...Additional analyses will evaluate progression-free survival, tumor response rates

Active Biotech, of Lund, Sweden, and Ipsen, of Paris, said they now plan to conduct the primary progression-free survival analysis for the 10TASQ10 global Phase III trial of tasquinimod in 2014, at the same time as the first interim overall survival analysis, when more mature data are available...The primary endpoint is to demonstrate a median progression-free survival increase from 50 percent to 65 percent

The open-label, pivotal trial will enroll 400 subjects at about 80 sites in Australia, Canada, China, Europe, Latin America and the U.S. The primary endpoint is progression-free survival, and secondary endpoints include overall survival and safety...The primary outcome is progression-free survival

The primary endpoint of the trial, which compares ibrutinib monotherapy to ofatumumab, will be improvement in progression-free survival

Northwest Biotherapeutics Inc., of Bethesda, Md., said that a patient treated with DCVax-L for glioblastoma multiforme in 2002 has celebrated his 10th anniversary of cancer-free survival

OncoGenex Pharmaceuticals Inc., of Vancouver, British Columbia, said an investigator-sponsored, randomized, double-blind, placebo-controlled Phase II trial of OGX-427 in non-small-cell lung cancer (NSCLC) will be initiated to evaluate whether the drug in combination with carboplatin and pemetrexed can extend progression-free survival